Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of E7090 in Japanese Subjects With Solid Tumors
jRCT2080222689Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tasurgratinib in Nonhematologic neoplasms and cancer (2 arms), sponsored by Eisai Co., Ltd. Started Dec 2014; status: completed.
02
Drugs
tasurgratinib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on jRCT2080222689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222689.